Skip to content

High Resolution Imaging for Early and Better Detection of Bladder Cancer

High Resolution Imaging for Early and Better Detection of Bladder Cancer

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02340650
Acronym
HRME_Bladder
Enrollment
37
Registered
2015-01-16
Start date
2015-04-30
Completion date
2020-09-30
Last updated
2021-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder Cancer

Keywords

suspicious bladder lesion, normal bladder tissue

Brief summary

The goal of this study is to develop, optimize, and validate a High Resolution Imaging System in the bladder that displays images in real-time, providing automated diagnostic criteria for bladder cancer screening. High resolution images of normal bladder tissue and suspicious bladder lesions will be collected from patients who present to the study site for clinical evaluation.

Interventions

DEVICEStandard High Resolution Microendoscope and/or Line-Scanning Confocal High Resolution Microendoscope

Sponsors

William Marsh Rice University
CollaboratorOTHER
The University of Texas Health Science Center, Houston
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosed with clinically suspicious bladder lesion or clinical finding; or who are undergoing cystoscopy as part of their routine clinical care. * Must be willing and able to participate and provide written informed consent * Women of childbearing age who have the possibility of being pregnant must have a negative pregnancy test prior to participation

Exclusion criteria

* Patient with sufficient evidence of cognitive impairment that limits the subject's ability to understand the protocol, provide informed consent, or to comply with the protocol procedures. * Women with the possibility of having the pregnancy. * Patients having acute infection. * Person with Lidocaine sensitivity.

Design outcomes

Primary

MeasureTime frame
Specificity of Bladder Cancer Detection Imagingbaseline (at the time of imaging)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 16, 2026